Anticipated Financial Overview: Predictions Regarding Eli Lilly's Upcoming Financial Statement
Eli Lilly and Company (LLY), a leading pharmaceutical company based in Indianapolis, Indiana, is gearing up to announce its Q2 2025 earnings on Thursday, Aug. 7. Analysts are expecting a significant jump in earnings per share (EPS) for the June 2025 quarter, with consensus estimates placing the figure around $5.55.
For fiscal year 2025, the anticipated profit per share is approximately $21.99, reflecting a substantial increase of 69.3% compared to $12.99 in fiscal 2024. Looking ahead to fiscal 2026, EPS is expected to grow by about 40% year-over-year, reaching approximately $30.79 per share.
| Metric | Estimate | |------------------------------|-----------------------------| | Q2 2025 EPS | ~$5.55 | | FY 2025 Profit Per Share | $21.99 | | FY 2026 EPS Growth | ~40%, to about $30.79-$32.28 |
These expectations reflect a strong growth outlook for Eli Lilly in the near term.
In Q1, LLY's EPS of $3.34 fell short of the forecasted figure by 5.1%. Despite this slight miss, the company's revenue surged 45.2% year-over-year to $12.7 billion in Q1, demonstrating robust performance in key areas such as diabetes, cancer, neuroscience, and immunology.
Wall Street analysts have a highly optimistic view of LLY's stock, with an overall "Strong Buy" rating. Among 26 analysts covering LLY, 20 recommend "Strong Buy," two indicate "Moderate Buy," and four suggest "Hold." The mean price target for LLY is $983.46, implying a 26.7% premium from the current levels.
However, shares of Eli Lilly plunged 11.7% on May 1 following its Q1 earnings release. Over the past 52 weeks, LLY has fallen 10.3%, lagging behind both the S&P 500 Index's 13.4% uptick and the Health Care Select Sector SPDR Fund's 10.2% drop over the same time frame.
It's worth noting that LLY has topped Wall Street's earnings estimates in two of the last four quarters, but missed on two other occasions. The company recently lowered its fiscal 2025 adjusted EPS guidance to a range of $20.78 to $22.28.
As investors await LLY's Q2 2025 earnings announcement, the company's strong growth prospects, coupled with analyst optimism, continue to make it an attractive investment opportunity.
[1] Yahoo Finance. (n.d.). Eli Lilly and Company (LLY) Valuation. Yahoo Finance. https://finance.yahoo.com/quote/LLY/valuation?p=LLY
[2] Cantor Fitzgerald. (n.d.). Eli Lilly and Company (LLY) Price Target. Yahoo Finance. https://finance.yahoo.com/quote/LLY/analysis?p=LLY
[3] FactSet. (n.d.). Eli Lilly and Company (LLY) Earnings Estimates Trend. Yahoo Finance. https://finance.yahoo.com/quote/LLY/earnings?p=LLY
Disclosure: The author of this article, Neharika Jain, did not have positions in any of the securities mentioned. All information and data in the article are solely for informational purposes. For more information, please view the Disclosure Policy on the website.
In the context of Eli Lilly's Q2 2025 earnings announcement, analysts' optimistic views and the company's strong growth prospects make it an enticing business opportunity for investors, particularly for those interested in the finance and investing sectors. Considering the anticipated profit per share for FY 2025 and the expected growth in FY 2026, Eli Lilly's future financial position appears to be quite robust, offering potential returns for those invested in business and investing.
